GH Research (NASDAQ:GHRS) Given New $32.00 Price Target at Stifel Nicolaus

GH Research (NASDAQ:GHRS) had its price objective hoisted by equities research analysts at Stifel Nicolaus from $18.00 to $32.00 in a research note issued on Thursday,Benzinga reports. The firm presently has a “buy” rating on the stock. Stifel Nicolaus’ target price would suggest a potential upside of 196.02% from the stock’s previous close.

A number of other analysts have also weighed in on the stock. HC Wainwright reissued a “buy” rating and issued a $40.00 price objective on shares of GH Research in a research report on Monday, January 27th. Cantor Fitzgerald began coverage on GH Research in a report on Thursday, February 13th. They issued an “overweight” rating and a $14.00 price target on the stock. Finally, Canaccord Genuity Group lowered their target price on shares of GH Research from $31.00 to $28.00 and set a “buy” rating for the company in a research note on Monday, November 18th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $30.60.

GH Research Stock Performance

GHRS stock traded down $0.16 during trading on Thursday, hitting $10.81. 44,196 shares of the company’s stock traded hands, compared to its average volume of 646,874. The stock has a market capitalization of $562.42 million, a price-to-earnings ratio of -13.70 and a beta of 0.93. GH Research has a 52 week low of $6.00 and a 52 week high of $20.50. The business has a fifty day simple moving average of $10.38 and a 200 day simple moving average of $9.19.

GH Research (NASDAQ:GHRS) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.06. Research analysts forecast that GH Research will post -0.8 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets bought a new stake in shares of GH Research in the 4th quarter valued at about $44,000. Two Sigma Investments LP bought a new position in GH Research in the fourth quarter worth approximately $117,000. Millennium Management LLC bought a new position in GH Research in the fourth quarter worth approximately $145,000. AdvisorShares Investments LLC lifted its holdings in GH Research by 15.4% during the fourth quarter. AdvisorShares Investments LLC now owns 36,011 shares of the company’s stock worth $252,000 after buying an additional 4,806 shares during the period. Finally, Northern Trust Corp boosted its position in GH Research by 26.8% during the 4th quarter. Northern Trust Corp now owns 40,834 shares of the company’s stock valued at $286,000 after acquiring an additional 8,641 shares in the last quarter. 56.90% of the stock is currently owned by institutional investors.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).